## Medical Management of Adenomyosis: First-Line Hormonal Therapy ### Overview Adenomyosis is characterized by ectopic endometrial glands and stroma within the myometrium, leading to dysmenorrhea, menorrhagia, and chronic pelvic pain. Medical management aims to suppress endometrial proliferation and reduce myometrial inflammation. **Key Point:** The levonorgestrel-releasing intrauterine device (LNG-IUD / Mirena) is the preferred first-line hormonal agent for adenomyosis, particularly in nulliparous women who wish to preserve fertility. ### Why LNG-IUD Is Superior #### 1. **High Local Progestin Concentration** - Releases 20 μg/day of levonorgestrel directly into the uterine cavity - Achieves 100–200× higher endometrial progestin levels than systemic therapy - Minimal systemic absorption (~10% of serum levels) #### 2. **Efficacy in Adenomyosis** - **Menorrhagia reduction:** 60–90% decrease in menstrual blood loss within 3–6 months - **Dysmenorrhea relief:** 50–70% of patients report significant pain reduction - **Mechanism:** Suppresses endometrial proliferation, reduces inflammatory cytokines (IL-6, IL-8), and attenuates myometrial contractility #### 3. **Fertility Preservation** - Does NOT prevent ovulation (ovarian function intact) - Does NOT impair tubal transport or endometrial receptivity after removal - Can be removed at any time if pregnancy is desired - **Clinical Pearl:** Fertility rates post-removal are comparable to pre-insertion baseline #### 4. **Safety Profile** - Minimal systemic hormonal side effects (no weight gain, no mood changes) - No increased thrombotic risk (unlike combined oral contraceptives) - Suitable for women with contraindications to systemic estrogen (e.g., migraine with aura, thrombophilia) ### Comparison with Other Hormonal Agents | Agent | Mechanism | Efficacy in Adenomyosis | Fertility Impact | Menorrhagia Control | |-------|-----------|------------------------|-----------------|--------------------| | **LNG-IUD** | High local progestin | Excellent (60–90% reduction) | Preserved | Excellent | | **COC** | Estrogen + progestin | Moderate (30–50% reduction) | Preserved | Moderate | | **MPA (Depo-Provera)** | Systemic progestin | Moderate–good | Delayed return to fertility | Good | | **Norethisterone acetate** | Systemic progestin | Moderate | Preserved | Moderate | **High-Yield:** LNG-IUD is superior to systemic progestins because local delivery avoids systemic side effects while achieving higher endometrial concentrations. ### Why Other Options Are Second-Line **Combined oral contraceptive pills (COC):** - Moderate efficacy in adenomyosis (30–50% menorrhagia reduction) - Contain estrogen, which may paradoxically stimulate adenomyotic lesions in some women - Acceptable but not preferred as first-line **Medroxyprogesterone acetate (MPA) injections:** - Systemic absorption causes weight gain, mood changes, and delayed return to fertility (6–12 months) - Not ideal in nulliparous women planning pregnancy **Norethisterone acetate:** - Systemic progestin with moderate efficacy - Inferior to LNG-IUD; used when IUD insertion is contraindicated ### Treatment Algorithm for Adenomyosis ```mermaid flowchart TD A[Adenomyosis diagnosis]:::outcome --> B{Menorrhagia + dysmenorrhea?}:::decision B -->|Yes| C[First-line: NSAIDs + tranexamic acid]:::action C --> D{Response?}:::decision D -->|Yes| E[Continue medical management]:::outcome D -->|No| F{Fertility desired?}:::decision F -->|Yes, nulliparous| G[LNG-IUD]:::action F -->|No, completed family| H[GnRH agonist or hysterectomy]:::action G --> I[Excellent pain/bleeding control]:::outcome H --> J[Definitive management]:::outcome ``` **Mnemonic:** **LNG-IUD = LOCAL, LONG-ACTING, LEVONORGESTREL** — the three L's that make it ideal for adenomyosis in fertility-conscious women. [cite:Berek & Novak's Gynecology 16e Ch 12; FIGO Consensus on Adenomyosis 2020]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.